Physician profile
Philip Locicero
NPI 1255097036
$1,231.99
in general payments reported to CMS, 2019-2025
13 companies · $541 in 2025
The $541 reported for 2025 was more than what 88% of Medical-Surgical (Registered Nurse) providers received nationally (typical 2025 total: $93.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $691 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $216.23 | 2024-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $204.18 | 2024-2025 | |
| Esperion Therapeutics, INC. | $163.95 | 2024 | Nexletol, Nexlizet |
| Astrazeneca Pharmaceuticals Lp | $118.57 | 2024-2025 | Airsupra |
| Alnylam Pharmaceuticals INC. | $108.93 | 2024-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.69 | 2024-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $90.68 | 2024-2025 | Voquezna |
| Amgen INC. | $65.89 | 2024-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $48.43 | 2024-2025 | |
| Glaxosmithkline, LLC. | $39.37 | 2024-2025 | Trelegy Ellipta |
| Pfizer INC. | $34.59 | 2025 | |
| Merck Sharp & Dohme LLC | $22.39 | 2024 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $21.09 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Locicero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.